Clinical appraisal of abiraterone in the treatment of metastatic prostatic cancer: patient considerations, novel opportunities, and future directions

Overview of attention for article published in OncoTargets and therapy, January 2013

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (88th percentile)
High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

twitter: 2 X users

patent: 4 patents

Citations

dimensions_citation: 14 Dimensions

Readers on

mendeley: 43 Mendeley

Summary X Patents Dimensions citations

So far, Altmetric has seen 4 patents that reference this research output.

Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer

Grant US-11491149-B2

United States of America

Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer

Grant US-11160796-B2

United States of America

Androgen receptor modulator and uses thereof

Grant AU-2019222864-B2

Australia

ANTI-ANDROGENS IN COMBINATION WITH ABIRATERONE ACETATE AND PREDNISONE FOR TREATING…

Application EP-3610876-A1

European Patent Office